Publications by authors named "Oluwafikayo O Olamigoke"
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation.
Int J Radiat Oncol Biol Phys
February 2022
Purpose: BRCA1/2 pathogenic variant (PV) mutations confer radiation sensitivity preclinically, but there are limited data regarding breast cancer outcomes after radiation therapy (RT) among patients with documented BRCA1/2 PV mutations versus no PV mutations.
Methods And Materials: This retrospective cohort study included women with clinical stage I-III breast cancer who received definitive surgery and RT and underwent BRCA1/2 genetic evaluation at the The University of Texas MD Anderson Cancer Center. Rates of locoregional recurrence (LRR), disease-specific death (DSD), toxicities, and second cancers were compared by BRCA1/2 PV status.
Article Synopsis
- The study examined oncologic outcomes and toxicity after radiation therapy (RT) in breast cancer patients with various germline mutations identified through multigene panel testing.
- Approximately 25.2% of the 286 patients had pathogenic variants (PVs), but no significant differences in overall survival, locoregional recurrence, or disease-specific death were observed among those with BRCA1/2 or non-BRCA1/2 mutations compared to those without mutations.
- The findings suggest that the toxicity and efficacy of RT in patients with germline mutations are comparable to those without mutations, indicating that RT can be safely used as a standard treatment option.